"From 2021 to 2023, 32 new Chinese medicine drugs have been approved for listing, and new Chinese medicine registration categories in 2023 have been approved for listing, the number of approvals continues to remain in the double digits, and the qualified rate of Chinese medicine sampling has maintained a high level in recent years." Zhang Boli, academician of the Chinese Academy of Engineering, said that in recent years, the Chinese medicine industry can make "very good progress", which is inseparable from the reform of the Chinese medicine review and approval system, but also because the quality awareness of enterprises is enhanced, the bold use of information means, and strive to achieve the production process can be traced and the production process can be monitored, so that the quality of the production of drugs is more guaranteed.
In the development of TCM modernization industry, the production link is particularly important. "New quality productivity" has become a hot word recently, and "scientific and technological innovation" is its important connotation, and the development of innovative technologies such as big data, intelligence and digitalization has also brought important development opportunities for the reform of traditional Chinese medicine productivity.
In addition to production, in the face of new drug development and key technology research, the research and development of traditional Chinese medicine is also inseparable from the construction of digital intelligence. Relevant studies show that at present, the basic research technology of Chinese medicine efficacy substances still cannot fully meet the needs of drug innovation and research, and efficient research methods are still under development and optimization. Therefore, digital intelligence research is one of the key links to support the high-quality sustainable development of Chinese medicine in the future.
Tasly, a leading domestic modern Chinese medicine enterprise, said that the digital transformation of enterprises is to promote the deep integration of digital technology and industry and promote new industrialization. The combination of traditional Chinese medicine and data large model helps to enhance the core competitiveness of the traditional Chinese medicine field, accelerate the digital transformation of the traditional Chinese medicine industry, and promote the deep mining and reconstruction of the data of all links of the traditional Chinese medicine industry chain.
New quality productivity promotes TCM inheritance and innovation
The quality of Chinese medicine products is the premise of ensuring the safety, effectiveness, stability and controllability of Chinese medicine products. The vigorous development of Chinese medicine production process and quality control technology is an important measure to ensure the quality of Chinese medicine products, and also a key path to lead the improvement of Chinese medicine products.
However, the complex and multi-component material system of traditional Chinese medicine products brings great challenges to production quality control. According to the relevant research published in the journal of Chinese Herbal Medicine, the quality of raw materials of traditional Chinese medicine products has natural variability, and how to use raw materials with large chemical composition differences to produce consistent quality traditional Chinese medicine products has always been a worldwide problem. By introducing the digital information of TCM prescription compatibility, pharmacodynamic ingredients, mechanism of action, dosage toxicity into the digital intelligent production system, quality index design, manufacturing process development, production process control model establishment, and intelligent production line construction and implementation can be quickly and accurately completed according to the needs of disease treatment. To ensure the manufacture of drugs that meet the expected research and development goals, and on this basis to achieve uniform and stable drug quality.
It is worth noting that the application of innovative technologies such as big data, intelligence and digitalization is the focus of this government work report: vigorously promote the construction of a modern industrial system, accelerate the development of new quality productivity, promote industrial innovation with scientific and technological innovation, accelerate the promotion of new industrialization, improve total factor productivity, and constantly create new growth drivers and new advantages for development. We will promote a new improvement in social productivity.
In recent years, the production of traditional Chinese medicine is continuing to promote the construction of digital intelligence, more noteworthy is that at present, the field of modern Chinese medicine has been a leader in the application of digital intelligence in actual production, such as in recent years, Tasly in intelligent manufacturing and lean production continued investment and development. According to the semi-annual report of 2023, Tasly has been continuously improving the digitalization of processes, quality standards and production processes, using digital technology throughout the entire life cycle of drugs, further improving production efficiency and reducing production costs, and forming an intelligent manufacturing technology system with modern Chinese medicine as the core. Digital intelligent transformation and upgrading has also brought obvious value to Tasly in terms of customer value, economic benefits and social benefits.
According to Tasly, due to the natural variability of medicinal materials, it focuses on the key issues of traditional Chinese medicine industrial manufacturing such as quality index design, process development, process control, and equipment development, and introduces digital intelligent technology to effectively solve the common problems of traditional Chinese medicine manufacturing in the whole process of multi-component integrated control and the whole industrial chain multi-element systematic control. The precision control of quality oriented by curative effect is realized. Through intelligent manufacturing, it ensures that the quality and efficacy of each drop pill product are consistent.
At the same time, digital intelligent production also helps to reduce costs and increase efficiency, Tasly pointed out that based on the above technical achievements, the company has built three intelligent workshops for traditional Chinese medicine extraction, solid preparations, and lyophilized powder needles, and the per capita production efficiency has been significantly improved.
In addition, the super high-speed dropping pill equipment independently developed by Tisly integrates multiple processes through digital technology to upgrade to a continuous intelligent production line, which reduces the floor area by 75%, the condensing medium used is also significantly reduced, the production cycle per thousand pieces is shortened by 45%, and the energy consumption per unit of output value is saved by 25%.
Modern Chinese medicine leading enterprises "take the lead" industry development
In addition to new quality productivity and standardized cultivation of traditional Chinese medicine, the inheritance and innovation of traditional Chinese medicine can not be separated from the industry's leading enterprises, which have a large social impact and industry driving role, and have an important demonstration and leading role in accelerating industrial innovation and development.
Experts from the Institute of Industrial Economics of the Chinese Academy of Social Sciences pointed out that the industry's leading enterprises affect the growth of other enterprises in the same industry through the knowledge spillover effect, but also improve their own production efficiency. Facts have also proved that the industry's leading enterprises have the demonstration role of "big with small", and have certain factor resource optimization allocation and product market integration capabilities in building a new development pattern, which can drive industry enterprises to actively explore the domestic market, and have a leading demonstration role in the high-quality development of the industry.
After years of R&D investment and development, Tasly has become a modern Chinese medicine leader. According to the national hospital sales database of Zhirongyun, Tasly ranks the top three among the top 10 hospital-end proprietary Chinese medicine enterprises in 2022. In addition, according to the drug statistics report of IQVIA Chinese Hospital (≥100 beds), in 2022, Tisly compound Danshen dropping pills ranked first in the Chinese medicine market for ischemic heart disease.
In January 2024, Tasly announced that one of its innovative stem cell drugs was approved by the State Food and Drug Administration to enter clinical trials, further enriching its cardiovascular pipeline reserves and strengthening its important position in the Chinese cardiovascular and cerebrovascular market.
Tianfeng Securities and other pharmaceutical research reports pointed out that "Tasly is an innovative pharmaceutical company with a deep layout of cardiovascular and cerebrovascular drugs." Making full use of its advantages in the coordinated development of the three categories of modern Chinese medicine, biological drugs and chemical drugs, aiming at the largest drug market of cardiovascular and cerebrovascular, it has built more than 30 kinds of drugs, and laid out China's cardiovascular and cerebrovascular circuit with full-cycle solutions and differentiation strategies, becoming the hidden champion of China's cardiovascular and cerebrovascular market.
Not only the star product advantage, the 2023 semi-annual report shows that Tasly also continues to stand firm in the first echelon of modern Chinese medicine research and development - through the "four-in-one" research and development model, it has a research and development pipeline covering 97 products in research, including 41 type 1 innovative drugs, and 39 have entered the clinical trial stage, 25 have been in the clinical phase II and III research stage.
Can have the advantages of modern Chinese medicine research and development, which may be inseparable from the construction of Tisly logarithmic intelligent research and development platform.
It is understood that Tasly integrates cutting-edge research and development resources such as global gene network, artificial intelligence, and biomedical big data, constantly improves the big data intelligent platform, builds a digital intelligence innovation function service network that combines biological big data with market demand, and promotes in-depth research on traditional Chinese medicine mechanism and combination drug screening research. The digital analysis technology of "gene network - target - pharmacodynamic component" was established.
Among them, Tasly launched the "Star Cloud Digital wisdom Traditional Chinese Medicine Solution", which provides digital wisdom traditional Chinese medicine solutions based on a one-stop computing platform and large model, and combines traditional Chinese medicine classics, mass literature information, clinical data, traditional Chinese medicine and natural product modernization research data, etc., to accelerate the innovation and transformation of traditional Chinese medicine, and solve the research pain points such as sparse and discrete traditional Chinese medicine information. Promote the inheritance of the treasure house of TCM knowledge.
According to reports, at present, Tisly is aiming at the key technologies of rapid and efficient creation of new Chinese medicine, breaking through the core technology of green intelligent manufacturing of the whole Chinese medicine industry chain, the key technology of Chinese medicine efficacy evaluation and international registration, and building a modern Chinese medicine intelligent manufacturing technology system, and using modern pharmaceutical research and development and quality control system as the carrier. It opens up a path of research and development of Chinese medicine products to the world. According to reports, at present, Tisly is aiming at the key technologies of rapid and efficient creation of new Chinese medicine, breaking through the core technology of green intelligent manufacturing of the whole Chinese medicine industry chain, the key technology of Chinese medicine efficacy evaluation and international registration, and building a modern Chinese medicine intelligent manufacturing technology system, and using modern pharmaceutical research and development and quality control system as the carrier. It opens up a path of research and development of Chinese medicine products to the world.
Tasly said that on the basis of the digitalization of modern Chinese medicine, Tasly will create a new paradigm for the research and development of "digital wisdom Chinese medicine", that is, on the basis of the digitalization of massive information of traditional Chinese medicine and patients, the theoretical knowledge and clinical experience of traditional Chinese medicine will be combined with modern technology such as big data and artificial intelligence to achieve "five perfections and three perfections", namely: Combination number intelligence, material base number intelligence, quantity poison effect number intelligence, production quality control number intelligence, consumption cognition number intelligence, and then to achieve fine drug use, production intelligence, accurate curative effect.
In the face of the current new cycle, Tasly is also accelerating scientific research and innovation in the irreplaceable bottleneck areas of the industry, promoting the continuous breakthrough of key technologies and underlying technologies in intelligent research and development, intelligent manufacturing and other fields, and promoting the transformation from information technology to digital intelligence, to achieve digital intelligence research and development, a higher level of intelligent manufacturing and smart marketing. And accelerate the transformation from high quality to strong brands.
Minsheng Securities Research Report further pointed out that under the background of policy support and gradual improvement of national recognition, the Chinese medicine industry has developed rapidly and the market has continued to expand. Based on the internationalization of modern Chinese medicine, Tasly has been deeply engaged in modern Chinese medicine for more than 20 years, and has a comprehensive layout of Chinese medicine, chemical medicine and biological medicine. As a leading enterprise in the modernization of Chinese medicine, the future is promising.
Source: The 21st Century Business Herald
